

HIV Immunity and Eradication, a Herrenhausen Symposium

Herrenhausen Palace Conference Center

Hanover, Germany

November 2-3, 2017

Conference Program

Thursday, November 2

- 8:00 a.m. Registration
- 8:55 a.m. Welcome Remarks

Keynote

Chair:

- 9:00 a.m. *Vaccines for HIV Prevention and Treatment*
Nelson Michael, U.S. Military HIV Research Program, USA

Session 1 Vaccines and antibodies

Chair:

- 10:00 a.m. *CD8+ T cell responses: Can they contribute to HIV/SIV cure?*
Louis Picker, Oregon Health & Science University, USA
- 10:30 a.m. *Virus-antibody co-evolution in HIV infected individuals*
Nicola Doria-Rose, National Institute of Health, USA
- 11:00 a.m. Coffee break
- 11:30 a.m. *Toward eliciting antibodies to order: reductionist HIV vaccine design to elicit broadly neutralizing antibodies with pre-specified genetic and structural features*
Bill Schief, Scripps Research Institute, USA
- 12:00 p.m. *Toward sustained, effective, and universal protection from HIV-1*
Mike Farzan, The Scripps Research Institute, USA
- 12:30 p.m. Lunch

Session 2 Cure research

Chair:

- 2:00 p.m. *Latency reversal and viral clearance: preliminary studies*
David Margolis, UNC HIV Cure Center, USA
- 2:30 p.m. *Reservoir markers for cure research and clinical trials*
Christine Rouzioux, Necker Hospital, France

- 3:00 p.m. *Approaches for detecting and targeting HIV*
Bonnie Howell, Merck, USA
- 3:15 p.m. **Coffee Break**
- 3:30 p.m. *Compartmentalization of immune recovery in terminal ileum and rectal gait with art in primary HIV infection*
John Thornhill, Imperial College London, UK

Session 3 Viral reservoirs

Chair:

- 3:45 p.m. *Tracking the HIV reservoir*
Monsef Benkirane, Institute of Human Genetics, France
- 4:15 p.m. *In vivo analysis of HIV reservoirs*
J. Victor Garcia, University of North Carolina at Chapel Hill, USA
- 4:45 p.m. *Viral dynamics of the peripheral latent reservoir after analytical treatment interruption*
Brenda Salantes, University of Pennsylvania, USA
- 5:00 p.m. *HIV-1 reservoirs in CD4 T cell subpopulations*
Mathias Lichterfeld, Harvard Medical School, USA
- 5:30 p.m. *Inhibition of HIV reactivation in brain cells by AAV-mediated delivery of CRISPR/Cas9*
Christine Kunze, Helmholtz Zentrum München, Germany
- 5:45 p.m. **Reception**
- 7:00 p.m. Close of day

Friday, November 3

Keynote

Chair:

- 9:00 a.m. *HIV-1 persists and evolves within lymph tissue due to low drug penetration*
Steven Wolinsky, Northwestern University, USA

Session 4 HIV transmission, restriction and pathogenesis

Chair:

- 10:00 a.m. *Role of type 1 interferons in restriction of HIV-1 transmission*
Persephone Borrow, University of Oxford, UK
- 10:30 a.m. *Eliminating productively and latently infected cells with antibodies*
Olivier Schwartz, Institute Pasteur, France

11:00 a.m. Coffee break

11:20 a.m. *C-type lectin receptors control HIV-1 infection and immunity*
Teunis Geijtenbeek, Academic Medical Center Amsterdam, The Netherlands

11:50 p.m. *HIV-1 restriction factors and viral countermeasures*
Frank Kirchhoff, Ulm University, Germany

12:20 p.m. *HIV-1 balances the fitness costs of disrupting the host actin cytoskeleton by ensuring systemic persistence after mucosal transmission*
Shariq Usmani, Massachusetts General Hospital, USA

12:35 p.m. Lunch and Poster Session

Session 5 Viral immunity

Chair:

2:15 p.m. *Shut down of T cell activity in chronic HIV infection*
Hendrik Streeck, Essen University Hospital, Germany

2:45 p.m. *NK cell mediated recognition of HIV-1*
Marcus Altfeld, Heinrich Pette Institute, Germany

3:15 p.m. *Understanding HIV persistence and Immunity using virus sequence analysis*
Eli Boritz, National Institute of Health, USA

3:45 p.m. Coffee Break

Session 6 Lessons from cohorts

Chair:

4:15 p.m. *Maturation and persistence of broadly neutralizing antibodies*
Penny Moore, National Institute for Communicable Disease, South Africa

4:45 p.m. *Immunological effects of tuberculosis and ART timing in highly immunosuppressed HIV+ patients*
Anne Goldfeld, Harvard University, USA

5:15 p.m. *Biomedical Factors influencing HIV risk in young women*
Jo-Ann Passmore, Institute of Infectious Disease and Molecular Medicine, South Africa

5:45 p.m. Close of conference